Evidence map›Paper›PMID 39814449›Full record

ArticleThe Journal of rheumatology2025

Serum Biomarkers of Pulmonary Damage and Risk for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Sung Hae Chang, Yong-Beom Park, Gregory C McDermott, Misti L Paudel, Keigo Hayashi, You-Jung Ha, Jeong Seok Lee, Min Uk Kim, Chan Ho Park, Ji-Won Kim and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. The prevalence of interstitial lung disease and bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sung Hae ChangS.H. Chang, MD, PhD, MPH, Soonchunhyang University, Division of Rheumatology, Department of Internal Medicine, Cheonan, South Korea, and Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity and Harvard Medical School, Boston, Massachusetts, USA, and Soonchunhyang University Cheonan Hospital, Division of Rheumatology, Department of Internal Medicine, Cheonan, South Korea.ORCID 0000-0002-7980-7194
Yong-Beom ParkY.B. Park, MD, PhD, J.W. Ha, MD, PhD, Yonsei University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea.ORCID 0000-0003-4695-8620
Gregory C McDermottG.C. McDermott, MD, MPH, M.L. Paudel, MPH, PhD, J.A. Sparks, MD, MMSc, Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-9750-5448
Misti L PaudelG.C. McDermott, MD, MPH, M.L. Paudel, MPH, PhD, J.A. Sparks, MD, MMSc, Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-8361-0650
Keigo HayashiK. Hayashi, MD, MPH, Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity and Harvard Medical School, Boston, Massachusetts, USA, and Okayama University Graduate School of Medicine, Okayama, Japan.ORCID 0000-0002-2935-6284
You-Jung HaY.J. Ha, MD, PhD, E.H. Kang, MD, PhD, MPH, Seoul National University Bundang Hospital, Division of Rheumatology, Department of Internal Medicine, Seongnam, South Korea.ORCID 0000-0001-6107-9523
Jeong Seok LeeJ.S. Lee, MD, PhD, Korea Advanced Institute of Science and Technology, KAIST, Graduate School of Medical Science and Engineering, Daejeon, South Korea.ORCID 0000-0001-8261-7044
Min Uk KimM.U. Kim, MD, SMG-SNU Boramae Medical Center, Department of Radiology, Seoul, South Korea.ORCID 0000-0003-0564-5724
Chan Ho ParkC.H. Park, MD, Soonchunhyang University College of Medicine, Department of Radiology, Cheonan, South Korea.ORCID 0000-0002-0653-4666
Ji-Won KimJ.W. Kim, MD, PhD, J.Y. Choe, MD, PhD, Catholic University of Daegu School of Medicine, Division of Rheumatology, Department of Internal Medicine, Daegu, South Korea.ORCID 0000-0002-0498-5762
Jang Woo HaY.B. Park, MD, PhD, J.W. Ha, MD, PhD, Yonsei University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea.ORCID 0000-0002-3307-5215
Sang Wan ChungS.W. Chung, MD, PhD, Y.A. Lee, MD, PhD, Kyung Hee University Hospital, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea.
Sung Won LeeS.W. Lee, MD, Soonchunhyang University Cheonan Hospital, Division of Rheumatology, Department of Internal Medicine, Cheonan, South Korea.
Eun Ha KangY.J. Ha, MD, PhD, E.H. Kang, MD, PhD, MPH, Seoul National University Bundang Hospital, Division of Rheumatology, Department of Internal Medicine, Seongnam, South Korea.ORCID 0000-0001-9697-1159
Yeon Ah LeeS.W. Chung, MD, PhD, Y.A. Lee, MD, PhD, Kyung Hee University Hospital, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea.ORCID 0000-0001-8007-9131
Jung-Yoon ChoeJ.W. Kim, MD, PhD, J.Y. Choe, MD, PhD, Catholic University of Daegu School of Medicine, Division of Rheumatology, Department of Internal Medicine, Daegu, South Korea.ORCID 0000-0003-0957-0395
Eun Young LeeE.Y. Lee, MD, PhD, Seoul National University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea. jsparks@bwh.harvard.edu elee@snu.ac.kr.ORCID 0000-0001-6975-8627
Jeffrey A SparksG.C. McDermott, MD, MPH, M.L. Paudel, MPH, PhD, J.A. Sparks, MD, MMSc, Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity and Harvard Medical School, Boston, Massachusetts, USA; jsparks@bwh.harvard.edu elee@snu.ac.kr.ORCID 0000-0002-5556-4618

Funding

MECHANISMS OF ARTHRITIC &DERMATOLOGY DISORDERST32AR007530 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael B. Brenner, Ellen M Gravallese · 1986 to 2026
$10.4M
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7M
Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular PhenotypesR01HL155522 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks, George R Washko · 2022 to 2026
$3.5M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
NHLBI NIH HHS R01 HL155522NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR077607NIAMS NIH HHS R01 AR080659NIAMS NIH HHS T32 AR007530
6 · The paper itself

Abstract

objectiveTo investigate baseline and change of pulmonary damage biomarkers (serum Krebs von den Lungen 6 [KL-6], human surfactant protein D [hSP-D], and matrix metalloproteinase 7 [MMP-7]) with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) progression.

methodsIn the Korean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) cohort, a prospective cohort, we enrolled patients with RA and ILD confirmed by chest computed tomography imaging and followed annually. ILD progression was defined as worsening in physiological and radiological domains of the 2022 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society guideline for progressive pulmonary fibrosis (PPF). Associations between biomarkers and RA-ILD progression were analyzed using multivariable Cox regression, adjusting for potential confounders.

resultsWe analyzed 136 patients with RA-ILD (mean age 66.5 yrs, 30% male, 60.3% with usual interstitial pneumonia pattern). During a median 3.0 years of follow-up, 47 patients (34.6%) experienced progression. Higher baseline KL-6 and hSP-D levels were associated with higher risk of ILD progression (multivariable hazard ratios [HRs] 1.37 [95% CI 1.03-1.82] and 1.51 [95% CI 1.09-2.08], respectively), whereas only the highest quartile of MMP-7 showed an increased risk (multivariable HR 2.60 [95% CI 1.07-6.33]). Increasing levels of serum KL-6 at 1 year showed the strongest association with progression (∆KL-6: multivariable HR 2.00 [95% CI 1.29-3.11]), additionally adjusting for baseline biomarker levels.

conclusionIn this first prospective study to apply PPF criteria to RA-ILD, 34.6% progressed over 3 years. Higher baseline KL-6 and hSP-D were associated with progression. In follow-up, greater change in KL-6 was associated with progression. Serial measurement of pulmonary damage biomarkers may predict RA-ILD progression and may be helpful in monitoring patients and treatment decisions.

Indexed as

Arthritis, RheumatoidLung Diseases, InterstitialMatrix Metalloproteinase 7Mucin-1Pulmonary Surfactant-Associated Protein DAgedBiomarkersDisease ProgressionFemaleHumansLungMaleMiddle AgedProspective StudiesTomography, X-Ray ComputedBiomarkersMatrix Metalloproteinase 7MMP7 protein, humanMUC1 protein, humanMucin-1Pulmonary Surfactant-Associated Protein Dbiological markersdisease progressioninterstitial lung diseasesmucin-1pulmonary surfactant-associated protein Drheumatoid arthritis

Identifiers

PMID39814449
PMCPMC11961329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.